Alamar Biosciences Inc.
Organization details
- Legal name
- Alamar Biosciences Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Information Technology
- SIC code
- 3826 — Laboratory Analytical Instruments
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Fremont
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALMR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002104204
- EIN
- 36-4899036
Board of directors
-
Frank Witney · DirectorSince 2026
-
Ian W. Ratcliffe · DirectorSince 2026
-
Nicholas Naclerio · DirectorSince 2026
-
Rebecca Chambers · DirectorSince 2026
-
Robert P. Ragusa · DirectorSince 2026
-
Shiping Chen · Director · Chief Operating OfficerSince 2026
-
Yuling Luo · Director · Chief Executive OfficerSince 2026
Chief executives
Board connections
2 of this board's directors also sit on 5 other boards. 1 is in the same sector.
- via Frank Witney
- via Robert P. Ragusa
-
Revvity Inc. Same sectorvia Frank Witney
- via Frank Witney
- via Robert P. Ragusa
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $7,999,996
- 2 purchases by 2 insiders
- Sold, last 12 months
- $44,561,405
- 120 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −1,946 | $29.89 | $58,166 |
| Nov 3, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −72,301 | $29.89 | $2,161,077 |
| Nov 3, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −16,870 | $29.89 | $504,244 |
| Nov 3, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −20,196 | $29.89 | $603,658 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −763 | $29.84 | $22,768 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −3 | $30.63 | $92 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −28,404 | $29.84 | $847,575 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −131 | $30.63 | $4,013 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −6,628 | $29.84 | $197,780 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −30 | $30.63 | $919 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −7,935 | $29.84 | $236,780 |
| Nov 2, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −36 | $30.63 | $1,103 |
| Oct 30, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −1,309 | $29.93 | $39,178 |
| Oct 30, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −1,080 | $30.70 | $33,156 |
| Oct 30, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Open-market sale | −92 | $31.96 | $2,940 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Alamar Biosciences Inc.
Who is the CEO of Alamar Biosciences Inc.?
Yuling Luo has been Alamar Biosciences Inc.'s Chief Executive Officer since April 2026.
How many directors are on Alamar Biosciences Inc.'s board?
Alamar Biosciences Inc.'s board has 7 directors: Frank Witney, Ian W. Ratcliffe, Nicholas Naclerio, Rebecca Chambers, Robert P. Ragusa, Shiping Chen and Yuling Luo.
Are Alamar Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, Alamar Biosciences Inc. insiders bought $8.0 million of shares in 2 purchases and sold $44.6 million of shares in 120 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="alamar-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.